CTi Biopharma Corp

CTi Biopharma — Cell Therapeutics — Shareholder Meeting (June 2003)

67 slides from CTi Biopharma's shareholder meeting presentation, Jun 25, 2003

  1. Slide 1: Welcome Shareholders & Guests

    Welcome Shareholders & Guests June 20, 2003

  2. Slide 2: Annual Shareholders Meeting

    Annual Shareholders Meeting James A. Bianco President and CEO (GRAPHIC) We’re fighting cancer

  3. Slide 3: Business Meeting Agenda

    Business Meeting Agenda Approve minutes Elect Directors Approve 2003 Equity Incentive Plan Approve an amendment to Employee Stock Purchase Plan Ratify selection of E&Y as independent auditors

  4. Slide 4: Business Meeting

    Business Meeting Call meeting to order Introduction of officers, directors, accountants, inspector of elections Record Date: May 7, 2003 Confirmation of quorum established

  5. Slide 5: Business Meeting: Approval of minutes

    Business Meeting Approval of minutes

  6. Slide 6: Election of Directors

    Business Meeting Election of class III Directors - Mary Mundinger - Jack Singer - Marty Sutter Election of class I Director - John Fluke

  7. Slide 7: Approve 2003 Equity Incentive Plan

    Business Meeting Approve 2003 Equity Incentive Plan

  8. Slide 8: Employee Stock Purchase Plan Amendment

    Business Meeting Approve amendment to the Company’s 1996 Employee Stock Purchase Plan to increase the number of shares by 150,000 to a total of approximately 635,000 shares

  9. Slide 9: Ratify Ernst & Young as Auditors

    Business Meeting Ratify selection of Ernst & Young as independent auditors Open the floor to motions

  10. Slide 10: Voting

    Business Meeting Voting Results of voting Conclusion of the business items

  11. Slide 11: Management Presentation

    Management Presentation [GRAHIC]

  12. Slide 12: Agenda

    Agenda Oncology Portfolio Strategy J. Bianco Market Dynamics - Hematology Market - Solid Tumor Market CTI-Novuspharma merger Commercial Development E. Kenney Research and Clinical Development J. Singer Closing Remarks J. Bianco

  13. Slide 13: Forward Looking Statement

    Forward Looking Statement This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and beliefs and are subject to a number of facto

  14. Slide 14: Where You Can Find Additional Information

    Where You Can Find Additional Information Cell Therapeutics, Inc. (CTI) will file a proxy statement/prospectus and other documents concerning the proposed merger transaction with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read the proxy statement/prospe

  15. Slide 15: Making Cancer More Treatable

    Making Cancer More Treatable Providing less toxic, more effective therapies to treat and cure cancer while permitting patients and their families to maintain their dignity and quality of life

  16. Slide 16: New Paradigm in Treating Cancer

    New Paradigm in Treating Cancer Improving treatment outcomes – four strategic directions Improving tolerability of existing chemotherapy agents Combining therapies to work more effectively without increased side effects Developing tumor targeted therapies exploiting human genome Treating cancer as a

  17. Slide 17: Oncology Strategy

    Oncology Strategy Improve the safety and efficacy of existing agents which provide the cornerstone for standard of care - Taxanes (>$2B) XYOTAX ™ - Camptothecins (>$1B) CT-2106 - Anthracyclines (>$500M) Pixantrone Develop new agents with unique mechanisms of tumor cell killing without more side effe

  18. Slide 18: Commercial Synergies

    Commercial Synergies Key Products Hematology Solid Tumors TRISENOX ® APL, CML, MDS, Multiple myeloma Pixantrone Aggressive NHL Indolent NHL Breast cancer Prostate cancer XYOTAX ™ NSC lung cancer Ovarian cancer CT-2106 Colorectal cancer Small cell lung cancer

  19. Slide 19: Hematology

    Hematology Commercial opportunity 2002 Incidence 2002 Prevalence Total Hematologic 94,850 423,564 TRISENOX ® APL 1,050 2,535 Myelodysplastic Syndromes 15,200 35,562 Multiple Myeloma 14,600 49,542 Pixantrone AML 10,600 18,980 Indolent NHL 24,030 142,625 Aggressive NHL 29,370 174,320

  20. Slide 20: Selected Companies Focused on Hematology Market

    Selected Companies Focused on Hematology Market Company Key Products Market Cap Genentech Rituxan ® $ 38 B Berlex* Campath ® , Fludara ® , Leukine ® $ 10 B Idec Zevalin ® , Rituxan ® $ 6.3 B Millennium Velcade ™ $ 4.7 B Celgene Thalomid ® , Revimid ™ $ 2.7 B CTI TRISENOX ® , Pixantrone $ 518 M 1 * S

  21. Slide 21: Hematology Market Dynamics

    Hematology Market Dynamics Few “big pharma” competitors in the space High incidence diseases with few good treatment options Concentrated target market - ~4,500 physicians allows maximum sales and marketing leverage Many agents used in combination therapy

  22. Slide 22: Oncology

    Oncology Commercial opportunity 2002 Incidence 2002 Prevalence Total Oncologic 516,144 3,132,334 XYOTAX ™ Advanced NSC lung 137,600 162,352 Ovarian 25,400 145,831 CT-2106 Small cell lung 34,380 57,983 Colorectal 147,500 930,083 Pixantrone Breast 212,600 1,836,085

  23. Slide 23: Companies Focused on Oncology-Chemotherapy Market

    Companies Focused on Oncology-Chemotherapy Market Company Key Products Market Cap Pfizer Camptosar ® $ 285 B GlaxoSmithKline Hycamtin ® , Navelbine ® $ 126 B Novartis Femara ™ , Aredia ® , Gleevec ™ , $ 117 B Sandostatin ® , Zometa ™ Astra-Zeneca Arimidex ® , Casodex ® , Faslodex ® , $ 78 B IRESSA ®

  24. Slide 24: Oncology Market Dynamics

    Oncology Market Dynamics “Big pharma” significant sales and marketing presence provides barrier to new marketer entry Novel breakthrough products rapidly adopted and can generate >$1B in annual sales Suggests partnership with multi-nationals for blockbuster product may maximize commercial potential

  25. Slide 25: Commercial Strategy

    Commercial Strategy Utilize TRISENOX ® to establish a commercial organization Expand TRISENOX ® indications to capture market share in blood related cancers (MDS, multiple myeloma) making commercial business profitable Acquire additional products with utility in blood related cancers to expand marke

  26. Slide 26: CTI-Novuspharma Merger

    CTI-Novuspharma Merger Immediate realizable synergies Pixantrone: commercially attractive phase III product - May qualify for FDA fast track - Potential NDA 2005, market launch 2006 - US sales could reach $150M+ Financially attractive - $120M in cash - $18-$20M in cost savings Significant operating

  27. Slide 27: Strong Financial Position

    Strong Financial Position Pro-forma end Q1 cash position $306 million - $111M cash Q1-2003 - $120M Novuspharma cash Q1-2003 - $75M convertible offering* - Exchange offer 12/02 retired $60M convertible debt Merger offers potential for cost synergies - $18M to $20M savings in 2004 TRISENOX ® U.S. busi

  28. Slide 28: Commercial Operations

    Commercial Operations Edward F. Kenney Executive Vice President Chief Operating Officer [GRAPHIC] We’re fighting cancer

  29. Slide 29: Trisenox

    Trisenox (arsenic trioxide) injection Indicated for the induction or remission and consolidation for patients with relapsed or refractory acute promyelocytic leukemia (APL) [GRAPHIC]

  30. Slide 30: TRISENOX

    TRISENOX ® Product approved US and EU 100% CAGR forecasted through 2003 $150+ million peak US sales potential Gaining US market share EU penetration limited to initial label (APL) Potential for MDS filing in 2004 allows for re-evaluation of EU commercial potential and strategy

  31. Slide 31: TRISENOX US Patient Mix

    TRISENOX US Patient Mix 1Q02 1Q03 APL 15% APL 10% Myeloma 43% Myeloma 43% MDS 29% MDS 41% Other 13% Other 6% [Graphic]

  32. Slide 32: TRISENOX Sales revenues & forecasts

    TRISENOX ® Sales revenues & forecasts $Millions $6.0M $11.7M $24M $43.0M 2003(E) 2004(E) Source for 2004 estimate: CIBC World Markets

  33. Slide 33: Solid Tumors

    Solid Tumors Commercial opportunity Taxanes - Taxol ® (paclitaxel), Taxotere ® (docetaxel) most widely used cancer drugs Worldwide sales exceed $2 billion Projected number of patients treated monthly - Paclitaxel – 54,700 - Docetaxel – 26,400 70% of taxane use is in 4 tumor types

  34. Slide 34: Worldwide Taxane Sales

    Worldwide Taxane Sales Paclitaxel $857M Sales 60% in ovarian and lung cancers Docetaxel $1,192M WW Sales 33% in ovarian and lung cancers

  35. Slide 35: US Taxane Sales

    US Taxane Sales ¨ Paclitaxel ¨ Docetaxel NSC Lung Cancer 36,526 pts/yr. (Docetaxel) $153M 50,134 pts/yr (Paclitaxel) $280M Ovarian Cancer 18,002 pts/yr (Paclitaxel) $195M Breast Cancer 17,837 pts/yr (Docetaxel) $244M 15,923 pts/yr (Paclitaxel) $173M

  36. Slide 36: XYOTAX (polyglutamate paclitaxel)

    XYOTAX (polyglutamate paclitaxel) A safer, potentially more effective taxane

  37. Slide 37: XYOTAX Target product profile

    XYOTAX ™ Target product profile XYOTAX Paclitaxel Docetaxel Premedications No Yes Yes Infusion time 10 mins 3 hrs 1 hr Special infusion kits No Yes Yes Hair loss No Yes Yes Neuropathy Infrequent Frequent Infrequent Tolerability Excellent Fair Fair Efficacy Superior — —

  38. Slide 38: Value Drivers

    Value Drivers Drivers of market share Strength of product attributes - Efficacy - Safety - Convenience Reimbursement/third-party provider support Price/dosing schedule for XYOTAX ™

  39. Slide 39: Commercial Growth

    Commercial Growth [GRAPHIC] TRISENOX ® APL label, > 40 trials , 2003 XYOTAX ™ Phase III trials , 2003 TRISENOX ® Potential MDS label , 2004 XYOTAX ™ Potential NDA , 2004 Pixantrone Phase III trials , TRISENOX ® Potential myeloma label , 2005 XYOTAX ™ Potential NSCLC label , 2005 Pixantrone Potential

  40. Slide 40: Research & Clinical Development

    Research & Clinical Development Jack W. Singer Executive Vice President Research Chair [GRAPHIC] We’re fighting cancer

  41. Slide 41: Oncology Pipeline

    Oncology Pipeline Preclinical Phase I Phase II Phase III NDA Marketed TRISENOX ® Approved for relapsed or refractory acute promyelocytic leukemia (APL) Multiple myeloma, myelodysplasia, myelogenous leukemia and other cancers XYOTAX ™ Non-small cell lung and ovarian cancers Pixantrone Non-Hodgkin’s l

  42. Slide 42: TRISENOX

    TRISENOX ® Initial label indication: relapsed/refractory APL Compelling efficacy in other hematologic cancers (multiple myeloma, MDS) Robust safety data base of over 2,300 patients - Manageable side effect profile >40 market expansion investigator sponsored trials targeting larger disease targets

  43. Slide 43: TRISENOX efficacy data in MDS

    TRISENOX ® Impressive efficacy data in MDS MDS (145 patients, 81 evaluable) 32% objective responses including high risk patients Decreases or eliminates RBC and platelet transfusion dependence - 80% of responding pts became transfusion independent lasting up to 2 yrs Well tolerated, no dose reductio

  44. Slide 44: TRISENOX efficacy data in multiple myeloma

    TRISENOX ® Impressive efficacy data in multiple myeloma Multiple myeloma (86 patients, 78 evaluable) High response rates in combination with dexamethasone, vitamin C, and melphalan - ~40% objective responses ( ³ PR) - ~70% disease control - Marked improvement in kidney function Well tolerated; manag

  45. Slide 45: XYOTAX

    XYOTAX ™ Safer, potentially more effective taxane Links paclitaxel to a “digestible” polymer Accumulates preferentially in tumor tissue Allows entry into cancer cells unlike standard paclitaxel 10-minute infusion into peripheral vein; no premedications required Robust clinical development program -

  46. Slide 46: XYOTAX Phase I/II clinical trials

    XYOTAX ™ Phase I/II clinical trials 7 phase I trials - Single agent - Combined with platinates - Every other week dosing - Combined with radiation 4 phase II trials - High risk NSC lung cancer - Chemotherapy resistant colorectal cancer - Chemotherapy resistant ovarian cancer - Relapsed/refractory br

  47. Slide 47: XYOTAX Registration strategy & timeline

    XYOTAX ™ Registration strategy & timeline XYOTAX ™ pivotal clinical trials to demonstrate - Superior survival compared to marketed taxanes in treatment of NSC lung cancer - Ease of use - Lower overall treatment costs - Lower incidence of severe side effects compared to approved agents Submit NSC lun

  48. Slide 48: Pixantrone

    Pixantrone (from Novuspharma merger) New DNA intercalator with improved efficacy and safety Now in phase III for NHL [GRAPHIC]

  49. Slide 49: DNA Intercalators

    DNA Intercalators Established efficacy - Cornerstone of chemotherapy for breast cancer, leukemias, and lymphomas - Standard treatment in blood-born tumors – curative - Breast cancer – highly effective as adjuvant and frontline therapy - Only therapy for advanced forms of multiple sclerosis However –

  50. Slide 50: DNA Intercalators with improved efficacy and safety

    DNA Intercalators with improved efficacy and safety Novuspharma’s approach - Alter chemical groups responsible for free-radical production and cardiac toxicity [GRAPHIC] Target markets - Unmet clinical need in second-line therapy (NHL) - Replace current DNA intercalators as safer treatment in first-

  51. Slide 51: Pixantrone

    Pixantrone Doxorubicin Mitoxantrone Pixantrone Efficacy in +++ ++ ++++ hematology Efficacy in ++/+++ ++ ++ solid tumors Safety + ++ ++++ (esp. cardiac) Superior anti-tumor activity in P388 and L1210 murine leukemias vs. Dx and Mitox Curative in YC-8 murine lymphoma Wide therapeutic window—effective

  52. Slide 52: Effect of pixantrone and mitoxantrone on survival

    Effect of pixantrone and mitoxantrone (MITOX) on survival in the YC-8 lymphoma model (iv/iv + 1,5,9) [Graphic]

  53. Slide 53: Pixantrone Experimental cardiotoxicity

    Pixantrone Experimental cardiotoxicity [Graphic]

  54. Slide 54: Pixantrone Target product profile

    Pixantrone Target product profile Superior safety - Cardiac toxicity profile superior to existing agents - Not toxic to tissues, eliminates need for central line - Less severe nausea and vomiting Impressive efficacy - Long lasting complete remissions in heavily treated NHL patients - As single agent

  55. Slide 55: Pixantrone

    Pixantrone Extensive clinical trial experience - >170 patients - 7 phase I, II trials Initial market entry into area of high unmet need - 3 rd -line aggressive NHL - Currently no approved therapies - Market size ~15,000 patients Potential label expansion - Relapsed indolent NHL + Rituxan ® (phase II

  56. Slide 56: Pixantrone single agent activity (NHL)

    Pixantrone Impressive single agent activity (NHL) High response rates in relapsed/resistant aggressive NHL - ORR= >30% (7CRs/5PRs + 5uPRs) - Durable responses: TTP >8 months for responders Well tolerated - Grade 4 neutropenia 13/33 (40%) - Grade 4 anemia/thrombocytopenia 0-1/33 (<3%) 28/33 (85%) had

  57. Slide 57: Pixantrone Combination trials

    Pixantrone Combination trials Highly active in combination regimens for relapsed/refractory NHL replacing doxorubicin - CHOP n=17 13 patients evaluable; 6CRs/1PR - ESHAP n=21 19 patients evaluable; 7CRs/4PRs Highly active in relapsed/refractory indolent NHL - FND-R n=9 - 6 patients evaluable; 5CRs/1

  58. Slide 58: Preliminary Market Study

    Preliminary Market Study % of physicians who would prescribe Pixantrone by line of therapy First Line Second Line Third Line Aggressive % % % Indolent % % % - Almost half of the physicians would try Pixantrone in place of doxorubicin in first line therapy for aggressive patients – mostly for patient

  59. Slide 59: CT-2106 Polyglutamate camptothecin

    CT-2106 Polyglutamate camptothecin Camptothecins (irinotecan, topotecan) approved for colorectal cancer, small cell lung cancer, and relapsed ovarian cancer Highly active class of drugs but limited by toxicity CT-2106 links 20S camptothecin to PG polymer Excellent activity and safety in animal studi

  60. Slide 60: LPAAT-ß

    LPAAT-ß Novel cancer target LPAAT-ß cloned and identified as a novel cancer target by CTI scientists Potential broad utility against many types of common cancers Preclinical studies of drug-like inhibitors selectively destroy cancerous cells Plenary presentations at three major cancer meetings in 20

  61. Slide 61: Closing Remarks

    Closing Remarks James A. Bianco President and CEO We’re fighting cancer [GRAPHIC]

  62. Slide 62: Last Months in Review

    Last 12 Months in Review Objective Acquire late stage or commercial product Reduce burn rate and secure adequate capital to grow commercial operations and see XYOTAX ™ to NDA Advance discussions toward potential XYOTAX ™ partner Initiate pivotal XYOTAX ™ phase III trials TRISENOX ® —profitable opera

  63. Slide 63: Key Objectives Next 12-18 Months

    Key Objectives Next 12-18 Months Gynecologic Oncology Group to initiate phase III study of XYOTAX ™ in ovarian cancer Complete enrollment of pivotal trials in non-small cell lung cancer Successful merger with Novuspharma to maximize cost synergies and efficiencies Initiate pivotal trial of Pixantron

  64. Slide 64: Key Objectives Next 12-18 Months

    Key Objectives Next 12-18 Months Explore TRISENOX ® label expansion in MDS in 2004 Grow TRISENOX ® sales >$40M Submit NDA for XYOTAX ™ Advance LPAAT inhibitors in development Secure global commercial partner for XYOTAX ™

  65. Slide 65: Stock Price Performance

    Stock Price Performance [Graphic]

  66. Slide 66: Community Involvement

    Community Involvement International Myeloma Foundation Education-Treatment-Research The Leukemia & Lymphoma Society Fighting Blood-Related Cancers MMRF Multiple Myeloma Research Foundation Gilda’s Club Worldwide The Friends of José Carreras International Leukemia Foundation Lance Armstrong Foundatio

  67. Slide 67: Making cancer more treatable

    [Graphic] cti Making cancer more treatable (c) 2003 Cell Therapeutics Inc

Cell Therapeutics — Shareholder Meeting (June 2003) on 6ix